ProgrammableTx, emerging from MIT and Cornell, is developing mRNA medicines for proteome editing. ProgrammableTx is built on two key pillars: computational design by AI/ML and state-of-the art protein engineering. From a protein sequence, we can identify in silico, high confidence protein binders to an unprecedented number of proteins, and protein isoforms. The in silico identified candidate peptide binders can be rapidly experimentally validated allowing for early-stage target validation. Like CRISPR guide RNAs, we can utilize our peptide binders (or other known protein-based binders) to direct different cellular mechanisms to a protein of interest allowing us to program biology in a directed manner. Our platform enables us to develop programmable therapeutics (think ubiquitination; stabilization phosphorylation;) in a single programmable, modular platform.